Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of PainTORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, today announced the publication of ...

Core Insights - Avicanna Inc. announces the resignation of Mr. Paul Fornazzari from its board of directors and the appointment of Mr. Michael Kott, effective January 1, 2026 [1][2] Group 1: Leadership Changes - Mr. Michael Kott brings over 35 years of experience in international capital markets, corporate finance, and fundraising, having founded CM-Equity AG, which transitioned into a global single-family office in 2025 [2] - Mr. Kott has a strong background in governance, compliance, capital markets transactions, IPOs, and cross-border investments, and is an active independent investor across various sectors including biopharma and technology [2] Group 2: Company Vision and Strategy - Mr. Kott expresses optimism about Avicanna's future, highlighting the company's position in the natural pharmaceuticals megatrend and the potential impact of recent communications from the White House regarding cannabis reclassification in the US [3] - The CEO of Avicanna, Aras Azadian, acknowledges Mr. Fornazzari's contributions and welcomes Mr. Kott, emphasizing the importance of his expertise in capital markets for the company's growth and shareholder value [4] Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing cannabinoid-based products for the global medical and pharmaceutical markets, with over thirty proprietary, evidence-based finished products [5] - The company operates a medical cannabis formulary (RHO Phyto™) and a medical cannabis care platform (MyMedi.ca), aimed at enhancing patient care and education [5] - Avicanna has a pharmaceutical pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [5]

Core Insights - Avicanna Inc. supports President Trump's executive order to reclassify cannabis from Schedule I to Schedule III, emphasizing the importance of scientific research in the field of cannabinoid-based medicine [2][3] - The company has made significant advancements in research and development (R&D), clinical development, and medical affairs, positioning itself for future growth and innovation in cannabinoid therapies [2][6] R&D and Clinical Development - Avicanna has established a scientific platform that includes over thirty proprietary, evidence-based finished products and supports four commercial stage business pillars [5] - The company is executing a balanced clinical development strategy, with approximately 450 patients enrolled in a real-world evidence study evaluating outcomes related to pain, sleep, anxiety, and depression [6] - A Phase II randomized controlled trial for evaluating arthritic pain using Avicanna's proprietary cannabinoid formulations commenced in December 2025 [6] Medical Affairs and Education - Avicanna has expanded its engagement with healthcare professionals through educational events and initiatives, contributing to improved patient access and support programs [6] - The MyMedi.ca platform aims to enhance the medical cannabis patient journey, providing bilingual pharmacist-led support and specialty services for distinct patient groups [9] Pharmaceutical Pipeline - The company has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [9] - Active pharmaceutical ingredients are supplied by Avicanna's subsidiary, Santa Marta Golden Hemp SAS, which provides high-quality CBD, THC, and CBG for various applications [9]

Core Insights - Avicanna Inc. supports President Trump's executive order to reclassify cannabis from Schedule I to Schedule III, emphasizing the importance of scientific research in the field of cannabinoid-based medicine [2][3] - The company has made significant advancements in research and development, clinical development, and medical affairs, positioning itself for future growth and innovation in cannabinoid therapies [3][6] R&D and Clinical Development - Avicanna has established a robust scientific platform leading to the commercialization of over thirty proprietary, evidence-based products, including a diverse range of cannabinoid formulations [5] - The company is executing a balanced clinical development strategy, with approximately 450 patients enrolled in a real-world evidence study evaluating outcomes related to pain, sleep, anxiety, and depression [6] - A Phase II randomized controlled trial for evaluating arthritic pain using Avicanna's proprietary formulations commenced in December 2025 [6] Medical Affairs and Education - Avicanna has expanded its engagement with healthcare professionals through educational events and initiatives, enhancing patient access and support programs [6][9] - The MyMedi.ca platform aims to improve the medical cannabis patient journey, offering bilingual pharmacist-led support and specialty services for distinct patient groups [9] Pharmaceutical Pipeline - The company is developing a pipeline of proprietary, indication-specific cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [9] - Avicanna's active pharmaceutical ingredients are supplied by its subsidiary, ensuring a reliable source of high-quality CBD, THC, and CBG for various applications [9]

Core Points - Avicanna Inc. has appointed Nick Hilborn as Interim Chief Financial Officer, succeeding Phillip Cardella who transitions to a consulting role [1][2] - The CEO, Aras Azadian, expressed gratitude for Cardella's contributions during transformative years and highlighted Hilborn's familiarity with the company and its culture [2] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the global medical and pharmaceutical markets [3] - The company has a scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products and four commercial stage business pillars [3] Product and Service Offerings - The RHO Phyto™ formulary includes a diverse range of proprietary products with various cannabinoid ratios, available nationwide in Canada and expanding internationally [6] - MyMedi.ca is a medical cannabis care platform aimed at enhancing the patient journey, featuring a diverse product portfolio and bilingual pharmacist-led support programs [6] - Avicanna has developed a pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [6] - The company’s subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality CBD, THC, and CBG for various applications, forming part of Avicanna's supply chain [6]

Core Insights - Avicanna Inc. has successfully completed its first export of organic certified non-psychoactive CBD dominant cannabis flower to Switzerland through its subsidiary Santa Marta Golden Hemp SAS, marking a significant milestone for the company [1][4] - This export expands the Aureus branded products to 20 international markets and Avicanna products to 23 markets, showcasing the company's ability to navigate complex regulatory environments for international commercialization [4][6] Company Developments - In 2024, Avicanna improved internal practices and local infrastructure at Santa Marta Golden Hemp SAS to enhance its portfolio of premium organic flower, responding to the increasing demand for medical cannabis in Europe and Australia [3] - The export included three proprietary cannabis varieties registered in Colombia, further validating the company's expertise in the cannabis sector [4] Product and Market Information - The Aureus brand encompasses a range of raw materials and active pharmaceutical ingredients (APIs) including CBD, CBG, and THC, which are essential for the company's supply chain and product offerings in consumer retail, medical cannabis, and pharmaceuticals [5][11] - Santa Marta Golden Hemp SAS has received Good Agricultural and Collection Practices (GACP) and Organic certifications under the USDA National Organic Program, ensuring high-quality input materials for various industries [6] Operational Capacity - The SMGH facility spans approximately 300,000 square feet with an extraction capacity of 300 kg, yielding around 26,400 kg annually, which supports the company's production capabilities [6]

Core Insights - re+PLAY is a CBD wellness brand founded by NBA veteran Al Harrington, utilizing Avicanna's proprietary CBD formulations [1][2] - The brand's initial product launch in the United States includes two products available online and at select retailers [1][2] - The collaboration between Avicanna LATAM SAS and Harrington Wellness focuses on developing CBD-based topicals for the athletic community [3][4] Company Overview - Avicanna LATAM SAS is a biopharmaceutical company based in Colombia, specializing in plant-derived cannabinoid products [2][6] - The company has a scientific platform that supports the development and commercialization of over thirty proprietary cannabinoid-based products [6] - Avicanna's subsidiaries include Santa Marta Golden Hemp, which provides high-quality CBD, THC, and CBG for various applications [6][7] Product Details - Initial re+PLAY products include a 3% CBD localized cream and a 2% CBD and 1% CBG transdermal gel, utilizing patented deep tissue technology [5] - The CBD and CBG in these formulations are derived from USDA organic certified hemp cultivated in Colombia [5] - The re+PLAY brand emphasizes THC-free products that have been endorsed by medical professionals and athletes [8]

Core Insights - The United States Patent and Trademark Office (USPTO) has issued Patent No. US 12,343,315 B2 to Avicanna Inc. for its topical cannabinoid compositions aimed at promoting clear skin [1][2] - The patent covers a topical gel formulation that combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents, targeting skin diseases such as acne, wrinkles, rosacea, and erythema [2] - Avicanna's CEO expressed enthusiasm about the patent, highlighting its potential in the company's commercial platforms and pharmaceutical pipeline [3] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4] - The company has a robust scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products [4] - Avicanna operates multiple business pillars, including a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and a subsidiary (Santa Marta Golden Hemp SAS) that supplies active pharmaceutical ingredients [4][7]

Core Viewpoint - Avicanna Inc. has successfully closed a non-brokered private placement offering, raising $1,000,000 through the sale of 4,000,000 units at a price of $0.25 per unit, which includes common shares and warrants [1][2]. Group 1: Offering Details - The offering consists of 4,000,000 units priced at $0.25 each, resulting in total gross proceeds of $1,000,000 [1]. - Each unit includes one common share and one-half of a common share purchase warrant, with the warrants allowing the purchase of one common share at an exercise price of $0.30 until July 16, 2028 [1]. - The securities from the offering are subject to a four-month hold period under Canadian securities laws and require necessary approvals, including from the Toronto Stock Exchange [3]. Group 2: Use of Proceeds - The proceeds from the offering will be allocated for general working capital, administrative expenses, production and manufacturing expenditures, and research and clinical development [2]. Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4]. - The company has a scientific platform that supports over thirty proprietary, evidence-based products and operates four commercial-stage business pillars [4]. - Avicanna's product offerings include a diverse range of cannabinoid-based formulations and a medical cannabis care platform aimed at enhancing patient experiences [6].

Core Viewpoint - Avicanna Inc. has successfully closed a non-brokered private placement offering, raising $1,000,000 through the sale of 4,000,000 units at a price of $0.25 per unit, which includes common shares and warrants [1][2]. Group 1: Offering Details - The offering consists of 4,000,000 units priced at $0.25 each, resulting in total gross proceeds of $1,000,000 [1]. - Each unit includes one common share and one-half of a common share purchase warrant, with the warrants allowing the purchase of additional shares at an exercise price of $0.30 until July 16, 2028 [1]. - The securities from the offering are subject to a four-month hold period under Canadian securities laws and require necessary approvals, including from the Toronto Stock Exchange [3]. Group 2: Use of Proceeds - The proceeds from the offering will be allocated for general working capital, administrative expenses, production and manufacturing costs, and research and clinical development [2]. Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4]. - The company has a scientific platform that supports over thirty proprietary products and operates four commercial-stage business pillars [4]. - Avicanna's product offerings include a diverse range of cannabinoid-based formulations and a medical cannabis care platform aimed at enhancing patient support and education [6].